Paying users zone. Data is covered by .
Get to Gilead Sciences Inc. for $17.99, or
get to entire website for at least 3 months from $49.99.
Enterprise Value to FCFF (EV/FCFF)
Free Cash Flow to The Firm (FCFF)
Gilead Sciences Inc., FCFF calculation
USD $ in millions
|FCFF||Free cash flow to the firm is the cash flow available to the Gilead Sciences Inc.’s suppliers of capital after all operating expenses have been paid and necessary investments in working and fixed capital have been made.||Gilead Sciences Inc.’s FCFF declined from 2015 to 2016 and from 2016 to 2017.|
Interest Paid, Net of Tax
Gilead Sciences Inc., interest paid, net of tax calculation
USD $ in millions
2 Interest paid, net of amounts capitalized, tax = Interest paid, net of amounts capitalized × EITR
= × =
Enterprise Value to FCFF Ratio, Current
Gilead Sciences Inc., current EV/FCFF calculation, comparison to benchmarks
|Selected Financial Data (USD $ in millions)|
|Enterprise value (EV)|
|Free cash flow to the firm (FCFF)|
|Bristol-Myers Squibb Co.|
|Eli Lilly & Co.|
|Johnson & Johnson|
|Merck & Co. Inc.|
|Regeneron Pharmaceuticals Inc.|
|Pharmaceuticals & Biotechnology|
Based on: 10-K (filing date: 2018-02-27).
If company EV/FCFF is lower then the EV/FCFF of benchmark then company is relatively undervalued.
Otherwise, if company EV/FCFF is higher then the EV/FCFF of benchmark then company is relatively overvalued.
Enterprise Value to FCFF Ratio, Historical
Gilead Sciences Inc., historical EV/FCFF calculation, comparison to benchmarks
3 EV/FCFF = EV ÷ FCFF
= ÷ =
|EV/FCFF||Enterprise value to free cash flow to the firm is whole company valuation indicator.||Gilead Sciences Inc.’s EV/FCFF ratio declined from 2015 to 2016 but then increased from 2016 to 2017 exceeding 2015 level.|